作者
Kai Neben, Anna Jauch, Thomas Hielscher, Jens Hillengass, Nicola Lehners, Anja Seckinger, Martin Granzow, Marc S Raab, Anthony D Ho, Hartmut Goldschmidt, Dirk Hose
发表日期
2013/12/1
期刊
Journal of clinical oncology
卷号
31
期号
34
页码范围
4325-4332
出版商
American Society of Clinical Oncology
简介
Purpose
The aim of this study was to analyze chromosomal aberrations in terms of frequency and impact on time to progression in patients with smoldering multiple myeloma (SMM) on the background of clinical prognostic factors.
Patients and Methods
The chromosomal abnormalities 1q21, 5p15/5q35, 9q34, 13q14.3, 15q22, 17p13, t(11;14)(q13;q32), and t(4;14)(p16.3;q32) were assessed in CD138-purified myeloma cells by interphase fluorescent in situ hybridization (iFISH) alongside clinical parameters in a consecutive series of 248 patients with SMM.
Results
The high-risk aberrations in active myeloma (ie, del(17p13), t(4;14), and +1q21) present in 6.1%, 8.9%, and 29.8% of patients significantly confer adverse prognosis in SMM with hazard ratios (HRs) of 2.90 (95% CI, 1.56 to 5.40), 2.28 (95% CI, 1.33 to 3.91), and 1.66 (95% CI, 1.08 to 2.54), respectively. Contrary to the conditions in active myeloma …
学术搜索中的文章
K Neben, A Jauch, T Hielscher, J Hillengass… - Journal of clinical oncology, 2013